Physician profile
Dean Eliott
NPI 1306883897
$249,966.28
in general payments reported to CMS, 2019-2025
20 companies · $41K in 2025
The $41K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $24K · 2021: $23K · 2022: $32K · 2023: $40K · 2024: $32K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $104K · Travel and Lodging: $4,519 · Food and Beverage: $3,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $104,314.90 |
| Travel and Lodging | $4,518.51 |
| Food and Beverage | $3,693.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $132,104.12 | 2019-2025 | Constellation, Ngenuity, Unity |
| Alcon Research LLC | $39,450.00 | 2019-2025 | Unity |
| Genentech USA, INC. | $19,394.91 | 2019-2023 | Susvimo |
| Dutch Ophthalmic, USA | $16,250.00 | 2019-2023 | Tissueblue, Eva, Combined Machine |
| Glaukos Corporation | $12,221.61 | 2019-2021 | |
| Allergan, INC. | $10,131.45 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $7,554.62 | 2023-2025 | Syfovre |
| Neurotech Pharmaceuticals, INC. | $4,733.40 | 2025 | Encelto |
| Ocular Therapeutix, INC. | $4,297.50 | 2025 | |
| Astellas Pharma US INC | $2,600.00 | 2025 | Izervay |
| Regeneron Pharmaceuticals, INC. | $384.30 | 2019-2024 | Eylea Hd |
| Genentech, INC. | $262.25 | 2021-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $127.16 | 2021 | |
| Eyepoint US, INC. | $114.45 | 2024 | |
| Alimera Sciences, INC. | $104.88 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $87.15 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Dompe US, INC. | $41.28 | 2023 | Oxervate |
| Abbvie INC. | $22.03 | 2025 | |
| Oculus Surgical INC. | $15.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Eliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.